Abstract
Increasing evidence supports the availability of transcatheter heart valve (THV) procedures for the management of structural heart disease in higher risk patients. The complexity of the patient populations and disease processes, the smaller case volumes and variety of devices, procedural approaches and techniques, and the associated high costs combine to pose significant challenges to provide health services.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
